Announcement on Convening the Q3 2026 Performance Briefing
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
(688428)"INNOCARE PHARMA LIMITED"Announcement on Convening the Q3 2026 Performance Briefing
Filed with SSE · Stock code 688428 ·
On 6ix: 6ix.com/news/688428innocare-pharma-limitedannouncement-on-convening-the-q3-2026-performance-briefing
Watch InnoCare Pharma's latest callInnocare Pharma (Shanghai:688428) Q2 2026 Earnings Call · Replay · Aug 24Read the transcript of Innocare Pharma (Shanghai:688428) Q2 2026 Earnings Call6ix is reading this filing.
View original source (Shanghai Stock Exchange)InnoCare Pharma Ltd. on 6ix
Story so far
- Announcement on Vesting Results for the First Vesting Period of the Reserved Grant under the 2024 STAR Market Restricted Share Incentive Plan and Listing of Shares
- Announcement on the Progress of Acquisition of the Remaining Equity in a Controlled Subsidiary
- Announcement on the Satisfaction of Vesting Conditions for the First Vesting Period of the Reserved Grant under the 2024 STAR Market Restricted Share Incentive Plan
Earlier from InnoCare Pharma
- Indicative Announcement on Change in Equity Interests of Shareholder Holding More Than 5% of the Shares Reaching 1% Threshold
- Announcement on Vesting Results for the First Vesting Period of the Reserved Grant under the 2024 STAR Market Restricted Share Incentive Plan and Listing of Shares
- InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA/ STEAP1 in China
- Announcement on the Progress of Acquisition of the Remaining Equity in a Controlled Subsidiary
- Announcement on the Satisfaction of Vesting Conditions for the First Vesting Period of the Reserved Grant under the 2024 STAR Market Restricted Share Incentive Plan
Follow InnoCare Pharma into a list and get an email when it puts out news.
Follow InnoCare Pharma